ClinicalTrials.gg
RecruitingNCT07434986TI-HPC-TLEUpdated Oct 16, 2026

Overnight TI in TLE

An interventional study of Non-invasive Temporal Interference (TI) Stimulation Targeting Bilateral Hippocampi in Temporal Lobe Epilepsy (TLE), Drug Resistant Epilepsy and Sleep, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Duke University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Epilepsy, Temporal Lobe with a site in United States — 10 open to participants now, 10 under way, none of them phase 3. Epilepsy, Temporal Lobe · United States.

Planned enrollment
7th of 19
20 · median 10
Started
2026
the only one that year
No phase
11 of 30
5 open now
Registered
29th of 30
by date
Lead sponsor
2 of 30
Duke University

Among the 30 studies in Epilepsy, Temporal Lobe with a site in United States, this one is the 7th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2026, is one of 11 with no phase, and was the 29th registered.

Epilepsy, Temporal Lobe

65 studies on the registry are indexed under Epilepsy, Temporal Lobe; 25 are open to participants now.

Browse Epilepsy, Temporal Lobe studies →

Open to participants now

10 of the 30 studies in Epilepsy, Temporal Lobe with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Epilepsy, Temporal Lobe studies recruiting now, 6 (32%) set no upper age limit and 9 (47%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Epilepsy, Temporal Lobe with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to gauge whether overnight, non-invasive temporal interference (TI) stimulation aimed at the hippocampus can reduce abnormal brain activity linked to seizures and improve sleep in adults with drug-resistant temporal lobe epilepsy. The main questions are:

Does overnight TI stimulation lower seizure-related EEG activity during sleep?

Does overnight TI stimulation improve sleep quality and sleep patterns measured overnight in the lab?

Researchers will compare each participant's nights without stimulation to nights with active stimulation, and will also look at a night after stimulation ends to see whether any changes last.

Participants will:

Stay in-lab for six days for overnight sleep and EEG monitoring

Have one night of monitoring without stimulation

Receive TI stimulation during sleep for several nights

Have another night of monitoring without stimulation after the stimulation nights

Complete brief questionnaires and thinking/memory tasks before and after the stimulation nights

Be checked for side effects and comfort during the study and at follow-up

03

Conditions studied

  • Temporal Lobe Epilepsy (TLE)
  • Drug Resistant Epilepsy
  • Sleep

Keywords

  • Epilepsy
  • Temporal Lobe
  • Epilepsy and Sleep
  • Drug Resistant Epilepsy
  • Temporal Interference
  • Stimulation
  • Hippocampus
  • Sleep
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 - 70 years
  • Diagnosis of focal drug-resistant temporal lobe epilepsy
  • Candidate for in-laboratory overnight monitoring with PSG and scalp EEG, with ability to comply with study procedures
  • Stable antiseizure medication regimen for at least 1 week prior to admission
  • Capacity to provide consent

Exclusion criteria

Exclusion Criteria:

  • Generalized epilepsy syndromes or primary generalized seizures
  • Recent status epilepticus, seizure clusters requiring emergency intervention, or other features indicating unacceptable risk for monitored participation
  • Uncontrolled psychiatric illness (e.g., acute psychosis, severe untreated depression with high suicide risk)
  • Implanted electronic or metallic devices incompatible with TI (e.g., certain pacemakers, cochlear implants) as per device manual
  • Severe obstructive sleep apnea requiring immediate CPAP initiation and not yet treated
  • Dermatologic disease at electrode sites or known contact allergy to electrode materials
  • Pregnancy or breastfeeding
  • Concurrent enrollment in other interventional neuromodulation or pharmacological trials likely to confound EEG or sleep outcomes
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Single Group: Overnight TI Stimulation and Within-Subject No-Stimulation Control Nights

    Single-group, within-subject protocol with in-laboratory overnight PSG and scalp EEG. Participants complete one baseline night with no stimulation, followed by three consecutive nights of active overnight temporal interference (TI) stimulation targeting bilateral hippocampi, then one post-treatment night with no stimulation to assess persistence. Evening and morning EEG biomarker recordings are collected throughout, with safety/tolerability monitoring and pre/post cognitive and mood assessments.

    Device: Non-invasive Temporal Interference (TI) Stimulation Targeting Bilateral Hippocampi

Interventions

  • DeviceNon-invasive Temporal Interference (TI) Stimulation Targeting Bilateral Hippocampi

    Non-invasive temporal interference (TI) electrical stimulation delivered overnight to target the bilateral hippocampi during in-laboratory polysomnography and scalp EEG monitoring. Stimulation is applied via a multi-channel, current-controlled stimulator using a scalp electrode montage planned with MRI-guided modeling. TI is delivered continuously from lights-off to lights-on for three consecutive nights, with gradual ramp-up and ramp-down at the start and end of each session. Stimulation parameters use kilohertz carrier currents arranged to produce an amplitude-modulated envelope at 130 Hz at each hippocampal target, with current adjusted within preset safety limits based on tolerability and impedance.

06

What researchers measure

Primary outcomes

  1. Change in Overnight Interictal Epileptiform Discharge (IED) Rate on Scalp EEG

    Overnight interictal epileptiform discharge (IED) rate (spikes per minute) computed from scalp EEG during sleep. IEDs will be identified using a standardized scoring pipeline, and the rate will be calculated as total IED count divided by total minutes of sleep (PSG-defined sleep time). Lower values indicate fewer epileptiform discharges (improvement). The primary comparison is baseline no-stimulation night versus the average of the active TI stimulation nights.

    Time frame: Baseline (Night 1, no stimulation) and during active TI stimulation nights (average of Nights 2-4, overnight sleep period).

Secondary outcomes

  1. PSG sleep outcomes - time in REM (rapid eye movement)

    Overnight polysomnography (PSG) measures of sleep stages and sleep quality/continuity. Higher sleep efficiency and lower fragmentation indicate improvement.

    Time frame: Night 1 (no stimulation), Nights 2-4 (active TI), and Night 5 (no stimulation), assessed over each overnight sleep period.

  2. PSG sleep outcomes - efficiency

    Overnight polysomnography (PSG) measures of sleep stages and sleep quality/continuity. Higher sleep efficiency and lower fragmentation indicate improvement.

    Time frame: Night 1 (no stimulation), Nights 2-4 (active TI), and Night 5 (no stimulation), assessed over each overnight sleep period.

  3. PSG sleep outcomes - wake after sleep onset

    Overnight polysomnography (PSG) measures of sleep stages and sleep quality/continuity. Higher sleep efficiency and lower fragmentation indicate improvement.

    Time frame: Night 1 (no stimulation), Nights 2-4 (active TI), and Night 5 (no stimulation), assessed over each overnight sleep period.

  4. PSG sleep outcomes - arousal index

    Overnight polysomnography (PSG) measures of sleep stages and sleep quality/continuity. Higher sleep efficiency and lower fragmentation indicate improvement.

    Time frame: Night 1 (no stimulation), Nights 2-4 (active TI), and Night 5 (no stimulation), assessed over each overnight sleep period.

  5. Morning and evening scalp EEG biomarker burden

    Standardized scalp EEG recordings collected twice daily to quantify seizure-related biomarker burden (e.g., IED rate) and track day-to-day changes during the monitoring week. Lower biomarker burden indicates improvement.

    Time frame: Evening (~20:00) and morning (~10:00) assessments across the in-lab week (Days 1-6)

  6. Persistence of biomarker changes after stimulation ends - Post treatment night

    Biomarker burden on the post-treatment no-stimulation night to assess whether overnight TI effects carry over after stimulation stops, compared with baseline and stimulation nights. Lower biomarker burden indicates improvement

    Time frame: Night 5 (no stimulation; overnight sleep period), compared with Night 1 and the average of Nights 2-4

  7. Cognitive performance - Rey/Taylor Figure-copy and immediate recall

    Scores on Rey/Taylor Figure copy and immediate recall to assess short-term changes in visuospatial construction and memory before versus after the stimulation block. Higher scores indicate better performance

    Time frame: Pre-stimulation (baseline, prior to Night 2) and post-stimulation (after Night 4 or on Day 6)

  8. Psychiatric symptom measures - Beck Anxiety Inventory (BAI)

    Scores on validated anxiety and depression scales to assess changes in symptoms before versus after the stimulation block. Lower scores indicate fewer symptoms.

    Time frame: Pre-stimulation (baseline, prior to Night 2) and post-stimulation (after Night 4 or on Day 6)

  9. Psychiatric symptom measures - Hamilton Anxiety Rating Scale (HAM-A)

    Scores on validated anxiety and depression scales to assess changes in symptoms before versus after the stimulation block. Lower scores indicate fewer symptoms.

    Time frame: Pre-stimulation (baseline, prior to Night 2) and post-stimulation (after Night 4 or on Day 6)

  10. Psychiatric symptom measures - Hamilton Depression Rating Scale (HAM-D)

    Scores on validated anxiety and depression scales to assess changes in symptoms before versus after the stimulation block. Lower scores indicate fewer symptoms.

    Time frame: Pre-stimulation (baseline, prior to Night 2) and post-stimulation (after Night 4 or on Day 6)

  11. Safety and tolerability - adverse events, skin checks, discomfort

    Frequency, type, and severity of device- and study-related adverse events (e.g., skin irritation, headache, dizziness, sleep disturbance), plus tolerability/comfort checks during the admission and at follow-up

    Time frame: During in-lab monitoring (Nights 1-5) and follow-up (Day 7)

07

Study locations

1 of 1 sites recruiting
  • Anphy Lab - Inside Hock Plaza
    Durham, North Carolina 27705, United States
    Recruiting
08

References and documents

Publications

  • Acerbo E, Jegou A, Luff C, Dzialecka P, Botzanowski B, Missey F, Ngom I, Lagarde S, Bartolomei F, Cassara A, Neufeld E, Jirsa V, Carron R, Grossman N, Williamson A. Focal non-invasive deep-brain stimulation with temporal interference for the suppression of epileptic biomarkers. Front Neurosci. 2022 Aug 17;16:945221. doi: 10.3389/fnins.2022.945221. eCollection 2022. PubMed 36061593 ↗
  • Roehri N, Pizzo F, Lagarde S, Lambert I, Nica A, McGonigal A, Giusiano B, Bartolomei F, Benar CG. High-frequency oscillations are not better biomarkers of epileptogenic tissues than spikes. Ann Neurol. 2018 Jan;83(1):84-97. doi: 10.1002/ana.25124. PubMed 29244226 ↗
  • Colombet B, Woodman M, Badier JM, Benar CG. AnyWave: a cross-platform and modular software for visualizing and processing electrophysiological signals. J Neurosci Methods. 2015 Mar 15;242:118-26. doi: 10.1016/j.jneumeth.2015.01.017. Epub 2015 Jan 19. PubMed 25614386 ↗
  • McLachlan RS, Pigott S, Tellez-Zenteno JF, Wiebe S, Parrent A. Bilateral hippocampal stimulation for intractable temporal lobe epilepsy: impact on seizures and memory. Epilepsia. 2010 Feb;51(2):304-7. doi: 10.1111/j.1528-1167.2009.02332.x. Epub 2009 Oct 8. PubMed 19817814 ↗
  • Voroslakos M, Takeuchi Y, Brinyiczki K, Zombori T, Oliva A, Fernandez-Ruiz A, Kozak G, Kincses ZT, Ivanyi B, Buzsaki G, Berenyi A. Direct effects of transcranial electric stimulation on brain circuits in rats and humans. Nat Commun. 2018 Feb 2;9(1):483. doi: 10.1038/s41467-018-02928-3. PubMed 29396478 ↗
  • Velasco AL, Velasco F, Velasco M, Trejo D, Castro G, Carrillo-Ruiz JD. Electrical stimulation of the hippocampal epileptic foci for seizure control: a double-blind, long-term follow-up study. Epilepsia. 2007 Oct;48(10):1895-903. doi: 10.1111/j.1528-1167.2007.01181.x. Epub 2007 Jul 18. PubMed 17634064 ↗
  • Missey F, Acerbo E, Dickey A, Trajlinek J, Studnicka O, Lubrano C, De Araujo E Silva M, Brady E, Vsiansky V, Szabo JP, Dolezalova I, Fabo D, Pail M, Gutekunst CA, Migliore R, Migliore M, Lagarde S, Carron R, Karimi F, Astorga R, Cassara A, Kuster N, Neufeld E, Bartolomei F, Pedersen NP, Gross R, Jirsa V, Drane D, Brazdil M, Williamson A. Non-invasive Temporal Interference Stimulation of the Hippocampus Suppresses Epileptic Biomarkers in Patients with Epilepsy: Biophysical Differences between Kilohertz and Amplitude Modulated Stimulation. medRxiv [Preprint]. 2025 Jan 14:2024.12.05.24303799. doi: 10.1101/2024.12.05.24303799. PubMed 39711722 ↗
  • Violante IR, Alania K, Cassara AM, Neufeld E, Acerbo E, Carron R, Williamson A, Kurtin DL, Rhodes E, Hampshire A, Kuster N, Boyden ES, Pascual-Leone A, Grossman N. Non-invasive temporal interference electrical stimulation of the human hippocampus. Nat Neurosci. 2023 Nov;26(11):1994-2004. doi: 10.1038/s41593-023-01456-8. Epub 2023 Oct 19. PubMed 37857775 ↗
  • Grossman N, Bono D, Dedic N, Kodandaramaiah SB, Rudenko A, Suk HJ, Cassara AM, Neufeld E, Kuster N, Tsai LH, Pascual-Leone A, Boyden ES. Noninvasive Deep Brain Stimulation via Temporally Interfering Electric Fields. Cell. 2017 Jun 1;169(6):1029-1041.e16. doi: 10.1016/j.cell.2017.05.024. PubMed 28575667 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Oct 2026; primary completion for Oct 2026, 0 months later.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 27, 2026
StartEst.
Oct 15, 2026was Jun 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Oct 30, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
Anphy Lab - Inside Hock Plaza is now Recruiting
Oct 16, 2026
Start date
Jun 1, 2026→Oct 15, 2026
Oct 16, 2026
Contact
Study contact changed: m•••@duke.edu · •••9021→b•••@duke.edu · •••9386; added b•••@duke.edu · •••7573. See the current contact
Oct 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Anphy Lab - Inside Hock Plaza · Durham, United StatesContact m•••@duke.edu · •••9021→b•••@duke.edu · •••9386Contact added b•••@duke.edu · •••7573
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    Anphy Lab - Inside Hock Plaza is now Recruiting
    Start date Jun 1, 2026→Oct 15, 2026
    Contact Study contact changed: m•••@duke.edu · •••9021→b•••@duke.edu · •••9386; added b•••@duke.edu · •••7573. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Anphy Lab - Inside Hock Plaza · Durham, United StatesContact m•••@duke.edu · •••9021→b•••@duke.edu · •••9386Contact added b•••@duke.edu · •••7573

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07434986
Lead sponsor
Duke University
Collaborators
St. Anne's University Hospital Brno, Czech Republic
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

Birgit Frauscher, MD, PhD
Contact
birgit.frauscher@duke.edu
919-613-9386
Bruna Kfoury, Pharm.D.
Contact
bk282@duke.edu
470-312-7573
Birgit Frauscher, MD / PD
principal investigator · Duke University
Adam Williamson, PhD
principal investigator · St. Anne's University Hospital, Brno Czechia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion